Literature DB >> 28239985

Salvage surgery for primary lung cancer after chemotherapy in octogenarians.

Haruaki Hino1, Takashi Nishimura1, Chiemi Usuki2, Manami Sazuka2, Takuya Ito1, Atsuko Seki3, Jun-Ichi Nitadori1,4, Hirokazu Yamada2, Tomio Arai3, Hiroshi Yamamoto3, Jun Nakajima1,4.   

Abstract

An 81-year-old female patient was admitted to our institute because of abnormal X-ray results. Chest computed tomography showed a 7.7 × 5.3 cm mass located in the left lower lobe and multiple swollen lymph nodes. 18F-fluorodeoxyglucose-positron emission tomography indicated high standard uptake values in the mass and swollen lymph nodes. The patient was diagnosed with stage cT3N2M0-IIIA squamous cell carcinoma. Although the patient had multiple lymph node metastases and severe obstructive pulmonary function, four cycles of platinum doublet chemotherapy were initially performed and no side effect greater than grade 3 was experienced. As the lung cancer was downstaged to ycT2aN0M0-IB and pulmonary function had improved, a bronchodilating preparation, an uneventful left lower lobectomy, and a lymphadenectomy were performed. The patient was discharged 39 days after surgery and exhibited good health for a year at pathological stage ypT1aN0M0-IA (Ef2).
© 2017 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Chemotherapy; octogenarian; salvage treatment

Mesh:

Year:  2017        PMID: 28239985      PMCID: PMC5415469          DOI: 10.1111/1759-7714.12423

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


Introduction

Several phase III randomized trials have demonstrated favorable results of salvage surgery after chemotherapy for advanced N2‐stage IIIA primary lung cancer compared with surgery alone.1, 2 Radical surgery for lung cancer in octogenarians has increasingly been performed recently in Japan.3 We report a case of successful salvage surgery after chemotherapy in an octogenarian cN2‐stage IIIA primary lung cancer patient.

Case report

An 81‐year‐old female patient with good performance status and without signs of senility was admitted as a result of an abnormal chest X‐ray, which showed a mass over 7 cm in diameter in the left lower field (Fig 1a). Chest computed tomography (CT) indicated swelling in multiple lymph nodes and 18F‐fluorodeoxyglucose‐positron emission tomography (FDG‐PET) displayed high standard uptake values (Fig 2a,b). A diagnosis of stage cT3N2M0‐IIIA primary squamous cell lung cancer was made (Fig 3a). Because of the multiple lymph node metastases (numbers 7, 10, and 11) and severe obstructive pulmonary function (vital capacity 1.69L [74.1%], forced expiratory volume in 1 second [FEV 1] 870 mL, FEV 1/forced vital capacity [FVC] 55.4%), four cycles of chemotherapy (carboplatin AUC 5, 290 mg/body day 1, tegafur‐gimeracil‐oteracil potassium [S‐1], 80 mg/body days 1–14) were performed each month and no side effects over grade 3 were observed. After chemotherapy, the main tumor had shrunk to 4.7 × 2.6 cm and the size and shape of the lymph nodes had decreased to within normal range. FDG‐PET showed diminished standard uptake values, resulting in stage ycT2aN0M0‐IB (Figs 1b, 2c,d). Good physical capacity was maintained and respiratory function was improved with a bronchodilating preparation (vital capacity 2.37L [106.8%], FEV 1 1220 mL, FEV1/FVC 56.0%); therefore, a left lower lobectomy, and a lymphadenectomy were performed uneventfully. Pathological findings revealed that the viable tumor was 1.4 cm in diameter (Ef2), staged as ypT1aN0M0‐IA (Fig 3b–d). Although the ambulatory patient was discharged 39 days after surgery because of rehabilitation and therapy for allergic bronchopulmonary aspergillosis, she was good in health with the same pretreatment and preoperative performance status, and did not experience recurrence from initial therapy for over a year.
Figure 1

(a) Pre‐chemotherapy chest X‐ray shows a mass in the left lower field. (b) Post‐chemotherapy chest X‐ray shows the reduced mass.

Figure 2

(a,b) Enhanced computed tomography and 18F‐fluorodeoxyglucose‐positron emission tomography pre‐chemotherapy shows multiple swollen hilar lymph nodes and high standard uptake values. (c,d) Computed tomography and 18F‐fluorodeoxyglucose‐positron emission tomography post‐chemotherapy shows reduced lymph nodes and decreased standard uptake values.

Figure 3

Macroscopic and microscopic view of the lung cancer. (a) A needle biopsy specimen before chemotherapy showed invasive keratinizing squamous cell carcinoma. Bar = 50 μm. (b) Resected specimen. The tumor had an irregular margin, approximately 1.4 × 1.0 cm, which mostly consisted of collapsed lung parenchyma with fibrosis and necrosis. The yellow granular appearance is a result of tumor necrosis (N). Arrowhead indicates a small focus of residual tumor. Bar = 1 cm. (c) Tumor necrosis with cholesterin clefts and ghost cells. Bar = 200 μm. (d) Residual squamous cell carcinoma with neutrophil inflammation. Bar = 50 μm.

(a) Pre‐chemotherapy chest X‐ray shows a mass in the left lower field. (b) Post‐chemotherapy chest X‐ray shows the reduced mass. (a,b) Enhanced computed tomography and 18F‐fluorodeoxyglucose‐positron emission tomography pre‐chemotherapy shows multiple swollen hilar lymph nodes and high standard uptake values. (c,d) Computed tomography and 18F‐fluorodeoxyglucose‐positron emission tomography post‐chemotherapy shows reduced lymph nodes and decreased standard uptake values. Macroscopic and microscopic view of the lung cancer. (a) A needle biopsy specimen before chemotherapy showed invasive keratinizing squamous cell carcinoma. Bar = 50 μm. (b) Resected specimen. The tumor had an irregular margin, approximately 1.4 × 1.0 cm, which mostly consisted of collapsed lung parenchyma with fibrosis and necrosis. The yellow granular appearance is a result of tumor necrosis (N). Arrowhead indicates a small focus of residual tumor. Bar = 1 cm. (c) Tumor necrosis with cholesterin clefts and ghost cells. Bar = 200 μm. (d) Residual squamous cell carcinoma with neutrophil inflammation. Bar = 50 μm.

Discussion

The age of lung cancer patients has been higher on average recently, and in Japan, after consideration of comorbidity, performance status, and mental state, greater numbers of octogenarians have undergone radical surgery, similar to treatment methods applied to younger generations.3 Surgical morbidity, mortality, and five‐year overall survival rates for octogenarians have been reported as 8.4–38.0%, 1.1–3.6%, and 27.0–65.9%, respectively.4, 5, 6, 7, 8 In a meta‐analysis of six eligible randomized studies, Berghmans et al. reported that a combination of induction chemotherapy and surgery was favorable to surgery alone (hazard ratio 0.69, 95% confidence interval 0.57–0.84).9 In our case, chemoradiation therapy was initially considered, but was felt to be an excessive burden considering the patient's age and frailty; therefore, radiation therapy was not performed. If chemotherapy could not be completed, radiation therapy might be added, depending on the case. Yoshioka et al. reported that patients with squamous cell carcinoma experienced longer median overall survival in a carboplatin plus S‐1 group than in a carboplatinpaclitaxel group (14.0 vs. 10.6 months).10 The former group had a significantly better level of quality of life compared with the latter, including elderly patients.11 Elderly patients, especially octogenarians, are generally excluded from chemotherapy because of safety, considering their frailty. Only a few reports have evaluated the use and response of chemotherapy in the elderly population.12 The European Organization for Research and Treatment of Cancer and International Society for Geriatric Oncology recommend the use of carboplatin‐based doublets in fit elderly patients.13 National Comprehensive Cancer Network (NCCN) guidelines recommend platinum‐doublet chemotherapy in patients with good performance status, regardless of age.14 In our case, chemotherapy was performed because of the patient's physical tolerability. After the chemotherapy proved effective and the patients’ respiratory function improved, curative surgery was performed without any complications. Selected physically tolerable octogenarians could undergo invasive therapy, as is usually applied to younger generations, which might gain acceptable results. Further study is required to elucidate the feasibility and short and long term results of salvage surgery after chemotherapy in greater numbers of octogenarians with lung cancer.

Disclosure

No authors report any conflict of interest.
  14 in total

1.  Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.

Authors:  Isamu Okamoto; Hiroshige Yoshioka; Satoshi Morita; Masahiko Ando; Koji Takeda; Takashi Seto; Nobuyuki Yamamoto; Hideo Saka; Kazuhiro Asami; Tomonori Hirashima; Shinzoh Kudoh; Miyako Satouchi; Norihiko Ikeda; Yasuo Iwamoto; Toshiyuki Sawa; Masaki Miyazaki; Kenji Tamura; Takayasu Kurata; Masahiro Fukuoka; Kazuhiko Nakagawa
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

2.  Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology.

Authors:  A G Pallis; C Gridelli; U Wedding; C Faivre-Finn; G Veronesi; M Jaklitsch; A Luciani; M O'Brien
Journal:  Ann Oncol       Date:  2014-03-16       Impact factor: 32.976

3.  Non-small cell lung cancer, version 2.2013.

Authors:  David S Ettinger; Wallace Akerley; Hossein Borghaei; Andrew C Chang; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Ramaswamy Govindan; Frederic W Grannis; Stefan C Grant; Leora Horn; Thierry M Jahan; Ritsuko Komaki; Feng-Ming Spring Kong; Mark G Kris; Lee M Krug; Rudy P Lackner; Inga T Lennes; Billy W Loo; Renato Martins; Gregory A Otterson; Jyoti D Patel; Mary C Pinder-Schenck; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Eric Rohren; Theresa A Shapiro; Scott J Swanson; Kurt Tauer; Douglas E Wood; Stephen C Yang; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2013-06-01       Impact factor: 11.908

4.  Surgical treatment of non-small cell lung cancer in octogenarians.

Authors:  Olivia Fanucchi; Marcello Carlo Ambrogi; Paolo Dini; Marco Lucchi; Franca Melfi; Federico Davini; Alfredo Mussi
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-02-05

5.  Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature.

Authors:  T Berghmans; M Paesmans; A P Meert; C Mascaux; P Lothaire; J J Lafitte; J P Sculier
Journal:  Lung Cancer       Date:  2005-07       Impact factor: 5.705

6.  Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer.

Authors:  Sung Hoon Sim; Yu Jung Kim; Se Hyun Kim; Bhumsuk Keam; Tae Min Kim; Se-Hoon Lee; Dong-Wan Kim; Dae Seog Heo; Jong Seok Lee
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-20       Impact factor: 4.553

7.  Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer.

Authors:  Alain Depierre; Bernard Milleron; Denis Moro-Sibilot; Sylvie Chevret; Elisabeth Quoix; Bernard Lebeau; Denis Braun; Jean-Luc Breton; Etienne Lemarié; Sylvie Gouva; Nadine Paillot; Jeanne-Marie Bréchot; Henri Janicot; François-Xavier Lebas; Philippe Terrioux; Jean Clavier; Pascal Foucher; Michel Monchâtre; Daniel Coëtmeur; Marie-Claude Level; Pascal Leclerc; François Blanchon; Jean-Michel Rodier; Luc Thiberville; Anne Villeneuve; Virginie Westeel; Claude Chastang
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

8.  A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209).

Authors:  Kanji Nagai; Ryosuke Tsuchiya; Takashi Mori; Hiroto Tada; Yukito Ichinose; Teruaki Koike; Harubumi Kato
Journal:  J Thorac Cardiovasc Surg       Date:  2003-02       Impact factor: 5.209

9.  Surgical resection for lung cancer in the octogenarian.

Authors:  Jeffrey L Port; Michael Kent; Robert J Korst; Paul C Lee; Matthew A Levin; Douglas Flieder; Nasser K Altorki
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

10.  Video-assisted thoracic surgery for clinical stage I lung cancer in octogenarians.

Authors:  Mingyon Mun; Tadasu Kohno
Journal:  Ann Thorac Surg       Date:  2008-02       Impact factor: 4.330

View more
  1 in total

1.  Salvage surgery for advanced non-small cell lung cancer after targeted therapy: A case series.

Authors:  Weian Song; Shouyin Di; Junqiang Liu; Boshi Fan; Jiahua Zhao; Shaohua Zhou; Siyu Chen; Hai Dong; Caiying Yue; Taiqian Gong
Journal:  Thorac Cancer       Date:  2020-02-28       Impact factor: 3.500

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.